Vigil Neuroscience, Inc.
NASDAQ Global SelectTotal Valuation
Vigil Neuroscience, Inc. carries a market capitalization of 375.71M, placing it among publicly traded companies globally. Its enterprise value stands at 295.10M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 375.71M |
| Enterprise Value | 295.10M |
Share Statistics
Vigil Neuroscience, Inc. currently has 46.67M shares outstanding.
| Shares Outstanding | 46.67M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.98 |
| P/TBV Ratio | 8.48 |
| P/FCF Ratio | -6.04 |
| P/OCF Ratio | -6.01 |
Financial Position
Vigil Neuroscience, Inc. maintains a current ratio of 2.06, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.06 |
| Quick Ratio | 1.98 |
| Debt / Equity | 30.15 |
| Debt / EBITDA | -0.13 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -94.45 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Vigil Neuroscience, Inc.'s stock has gained approximately 136.76471% over the past 52 weeks. The 50-day moving average sits at 7.97, while the 200-day moving average is 3.80.
| Beta (5Y) | N/A |
| 52-Week Price Change | 136.76471% |
| 50-Day Moving Average | 7.97 |
| 200-Day Moving Average | 3.80 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -96.27M, while operating income came in at -96.75M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -96.75M |
| Pretax Income | -92.16M |
| Net Income | -92.16M |
| EBITDA | -96.27M |
| EBIT | -96.75M |
| Earnings Per Share (EPS) | -2.10 |
Balance Sheet
Vigil Neuroscience, Inc. holds 66.99M in cash and equivalents against 12.44M in total debt, resulting in a net debt position of -41.21M. Total book value stands at -356.10M, with working capital of 36.18M providing operational flexibility.
| Cash & Cash Equivalents | 66.99M |
| Total Debt | 12.44M |
| Net Debt | -41.21M |
| Equity (Book Value) | -356.10M |
| Book Value Per Share | -8.10 |
| Working Capital | 36.18M |
Cash Flow
Vigil Neuroscience, Inc. produced -58.21M in operating cash flow over the past twelve months. After subtracting -354,000.00 in capital expenditures, free cash flow totaled -58.57M - equivalent to -1.33 per share.
| Operating Cash Flow | -58.21M |
| Capital Expenditures | -354,000.00 |
| Free Cash Flow | -58.57M |
| FCF Per Share | -1.33 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -10.82 |
| FCF Yield | -16.55 |
Scores
Vigil Neuroscience, Inc. posts an Altman Z-Score of -4.32, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.32 |